Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Keros Therapeutics, Inc.NASDAQ: KROS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$23.71M, compared with $148.45M a year earlier. Trailing-twelve-month net income was -$85.15M.
Context
- Net income amounted to 35.7% of revenue in FY2025, down 5241.9 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$157.78M (-281.3%) for the fiscal year ending Dec 2026, a slowdown from the +146.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.71M+1.1% QoQ
- Last fiscal yearDec 2025
- $87.01M+146.4% YoY
- LTMMar 2026
- -$85.15M-2121.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -116.0% | -11.2% | +104.8 pp |
| 1 year | +146.4% | -281.3% | -427.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 87.01M USD
- Year-over-year change
- +146.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 87.01M | +146.4% |
| FY2024 | 2024-12-31 | (187.35M) | -22.5% |
| FY2023 | 2023-12-31 | (152.99M) | -46.2% |
| FY2022 | 2022-12-31 | (104.68M) | -78.2% |
| FY2021 | 2021-12-31 | (58.74M) | — |
Net Income vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 net income of $85.15M is the 7th largest of the 10 companies compared; the peer median is $118.44M.
- Its year-over-year change of -2121.5% is the lowest of 10, against a peer median of +32.1%.
- Net income amounts to 256.6% of revenue for KROS, versus a peer median of 248.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Mar 2026 | $290.01M | +83.9% | -11.6% | 330.2% | |
| LTM Mar 2026 | $259.47M | +76.5% | +66.1% | — | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
| LTM Mar 2026 | $185.15M | +43.6% | +15.7% | — | |
| LTM Mar 2026 | $118.44M | +10.2% | +3.2% | 6450.8% | |
| LTM Mar 2026 | $85.15M | -2121.5% | — | 256.6% | |
| LTM Mar 2026 | $59.14M | -242.2% | -44.1% | 166.4% | |
| LTM Mar 2026 | $44.17M | +6.7% | -28.2% | — | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $18.64M | +32.1% | — | 14.3% |
| Peer median (excluding KROS) | $118.44M | +32.1% | +3.2% | 248.3% | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| Deferred Income Tax | 46K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.72M | 18.68M | 28.76M | 34.87M | 28.7M |
| Change in Working Capital | (16.07M) | 14.31M | (2.65M) | (11.44M) | (12.11M) |
| Accounts Receivables | (18M) | 18M | (143K) | (2.6M) | (825K) |
| Inventory | 1.04M | 0 | (4.51M) | 0 | 0 |
| Accounts Payables | 1.49M | (408K) | 1.61M | (249K) | (3M) |
| Other Working Capital | (597K) | (3.28M) | 384K | (8.59M) | (8.29M) |
| Other Non-Cash Items | 520K | 953K | 1.56M | 1.82M | 2.4M |
| Operating Cash Flow | (62.15M) | (70.06M) | (124.51M) | (160.87M) | 107.51M |
| Capital Expenditures | (1.02M) | (1.24M) | (2.46M) | (1.93M) | (1.55M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.02M) | (1.24M) | (2.46M) | (1.93M) | (1.55M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 28.17M | 119.58M | 175.83M | 380.13M | (3.47M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (375M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 379K | 731K | 3.13M | 11.69M | 0 |
| Financing Cash Flow | 28.55M | 120.31M | 178.96M | 391.82M | (378.47M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.62M) | 49.01M | 51.98M | 229.02M | (272.52M) |
| Free Cash Flow | (63.17M) | (71.3M) | (126.97M) | (162.8M) | 105.95M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.